These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36588706)

  • 21. Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity.
    Xin X; Cheng C; Bei-Yu C; Hong-Shan L; Hua-Jie T; Xin W; Zi-Ming A; Qin-Mei S; Yi-Yang H; Qin F
    Front Nutr; 2021; 8():784354. PubMed ID: 34881283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
    Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
    PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
    Li H; Xi Y; Liu H; Xin X
    Front Nutr; 2022; 9():914079. PubMed ID: 36091227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
    Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
    Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
    Stokman G; van den Hoek AM; Denker Thorbekk D; Pieterman EJ; Skovgård Veidal S; Basta B; Iruarrizaga-Lejarreta M; van der Hoorn JW; Verschuren L; Berbée JFP; Rensen PCN; Skjaeret T; Alonso C; Feigh M; Kastelein JJP; Friedman SL; Princen HMG; Fraser DA
    Liver Int; 2020 Nov; 40(11):2860-2876. PubMed ID: 32841505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
    Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
    PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice.
    Sun H; Seok S; Jung H; Kemper B; Kemper JK
    Mol Metab; 2022 Dec; 66():101603. PubMed ID: 36126896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice.
    Morrison MC; Verschuren L; Salic K; Verheij J; Menke A; Wielinga PY; Iruarrizaga-Lejarreta M; Gole L; Yu WM; Turner S; Caspers MPM; Martínez-Arranz I; Pieterman E; Stoop R; van Koppen A; van den Hoek AM; Mato JM; Hanemaaijer R; Alonso C; Kleemann R
    Hepatol Commun; 2018 Dec; 2(12):1513-1532. PubMed ID: 30556039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.
    Henkel J; Coleman CD; Schraplau A; Jӧhrens K; Weber D; Castro JP; Hugo M; Schulz TJ; Krämer S; Schürmann A; Püschel GP
    Mol Med; 2017 May; 23():70-82. PubMed ID: 28332698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
    Hameed B; Terrault NA; Gill RM; Loomba R; Chalasani N; Hoofnagle JH; Van Natta ML;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):645-656. PubMed ID: 29333665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
    Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
    Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.
    Yang ZY; Liu F; Liu PH; Guo WJ; Xiong GY; Pan H; Wei L
    Int J Clin Exp Pathol; 2017; 10(8):8119-8129. PubMed ID: 31966664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.